Voluntary market withdrawal: Oxbryta (Pfizer – October)

Oct. 2024Pharmacy Updates

Pfizer Inc. is withdrawing Oxybryta from the market. Oxbryta is used for the treatment of sickle cell disease in adults and children 12 years old and older. Sickle cell disease affects the shape of red blood cells, which carry oxygen to all parts of the body.

This drug is being withdrawn from the market because recent data show the benefit of taking Oxbryta does not outweigh the risks. In clinical trials, there was a larger number of patients with severe pain because of less blood flow.

The Food and Drug Administration (FDA) has been conducting a safety review of Oxybryta and will communicate any additional findings when the review is complete. The FDA encourages health care professionals and patients to report adverse events or quality problems experienced with the use of Oxbryta.

There are other FDA-approved medications for the treatment of sickle cell disease. The FDA advises that you should contact your doctor or health care professional about stopping Oxbryta and starting another treatment option.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Visit the FDA website.

Recent Announcements

CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care

Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.
Feb. 2026Education/Webinars

Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions

Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.
Feb. 2026Education/Webinars

February 2026 UPMC for You and UPMC Community HealthChoices formulary update

Pulmicort Flexhaler has a new distributor, Rubicon Holding. National Drug Codes (NDCs) for Pulmicort Flexhaler from Rubicon Holding are not included in the Medicaid Drug Rebate program and are not covered under the Medicaid Prescription Drug Program. Pulmicort Flexhaler NDCs from the previous manufacturer, H2 Pharma, have been discontinued but may be billed/dispensed until supplies are exhausted.
Feb. 2026Pharmacy Updates